Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more
Pacira BioSciences, Inc. (PCRX) - Total Assets
Latest total assets as of December 2025: $1.26 Billion USD
Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) holds total assets worth $1.26 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pacira BioSciences, Inc. - Total Assets Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pacira BioSciences, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Pacira BioSciences, Inc.'s total assets of $1.26 Billion consist of 43.3% current assets and 56.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.5% |
| Accounts Receivable | $124.07 Million | 9.8% |
| Inventory | $152.86 Million | 12.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $368.10 Million | 29.1% |
| Goodwill | $20.21 Million | 1.6% |
Asset Composition Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pacira BioSciences, Inc.'s current assets represent 43.3% of total assets in 2025, an increase from 38.3% in 2008.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2025, down from 24.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 25.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 29.1% of total assets.
Pacira BioSciences, Inc. Competitors by Total Assets
Key competitors of Pacira BioSciences, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Pacira BioSciences, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Pacira BioSciences, Inc. generates 0.57x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Pacira BioSciences, Inc. generates $ 0.56 in net profit.
Pacira BioSciences, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.54 | 2.40 | 3.10 |
| Quick Ratio | 3.28 | 2.00 | 2.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $427.38 Million | $ 435.21 Million | $ 488.16 Million |
Pacira BioSciences, Inc. - Advanced Valuation Insights
This section examines the relationship between Pacira BioSciences, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.29 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | -18.6% |
| Total Assets | $1.26 Billion |
| Market Capitalization | $764.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pacira BioSciences, Inc.'s assets below their book value (0.60 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pacira BioSciences, Inc.'s assets decreased by 18.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual total assets of Pacira BioSciences, Inc. from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.26 Billion | -18.58% |
| 2024-12-31 | $1.55 Billion | -1.33% |
| 2023-12-31 | $1.57 Billion | -6.35% |
| 2022-12-31 | $1.68 Billion | -18.99% |
| 2021-12-31 | $2.08 Billion | +62.83% |
| 2020-12-31 | $1.27 Billion | +53.36% |
| 2019-12-31 | $831.07 Million | +20.56% |
| 2018-12-31 | $689.35 Million | +9.70% |
| 2017-12-31 | $628.37 Million | +60.52% |
| 2016-12-31 | $391.47 Million | +0.47% |
| 2015-12-31 | $389.62 Million | +19.49% |
| 2014-12-31 | $326.07 Million | +92.01% |
| 2013-12-31 | $169.82 Million | +51.55% |
| 2012-12-31 | $112.05 Million | -1.27% |
| 2011-12-31 | $113.49 Million | +70.50% |
| 2010-12-31 | $66.56 Million | +51.44% |
| 2009-12-31 | $43.95 Million | -13.03% |
| 2008-12-31 | $50.54 Million | -- |